Israel - English - Ministry of Health

novartis israel ltd - deferoxamine mesylate - powder for solution for inj/inf - deferoxamine mesylate 0.5 g/vial - deferoxamine - treatment of chronic iron overload e.g.: transfusional haemosiderosis especially in thalassaemia major sideroblastic anaemia autoimmune haemolytic anaemia and other chronic anaemias idiopathic (primary) haemochromatosis in patients in whom concomitant disorders ( e.g. severe anaemia cardiac disease hypoproteinaemia) preclude phlebotomy iron overload associated with porphyria cutanea tarda. treatment of acute iron poisoning. treatment of chronic aluminium overload in patients with terminal renal failure (under maintenance dialysis) with: aluminium-related bone disease and/or dialysis encephalopathy and/or aluminium-related anaemia. diagnosis of iron overload.

Israel - English - Ministry of Health

novartis israel ltd - deferoxamine mesylate - powder for solution for inj/inf - deferoxamine mesylate 0.5 g/vial - deferoxamine - treatment of chronic iron overload e.g.: transfusional haemosiderosis especially in thalassaemia major sideroblastic anaemia autoimmune haemolytic anaemia and other chronic anaemias idiopathic (primary) haemochromatosis in patients in whom concomitant disorders ( e.g. severe anaemia cardiac disease hypoproteinaemia) preclude phlebotomy iron overload associated with porphyria cutanea tarda. treatment of acute iron poisoning. treatment of chronic aluminium overload in patients with terminal renal failure (under maintenance dialysis) with: aluminium-related bone disease and/or dialysis encephalopathy and/or aluminium-related anaemia. diagnosis of iron overload.

Malta - English - Medicines Authority

novartis pharmaceuticals uk limited - deferoxamine 500 mg - powder for solution for injection

Malta - English - Medicines Authority

novartis ireland limited vista building, elm park, merrion road, ballsbridge, dublin 4,, ireland - deferoxamine - powder for solution for injection - deferoxamine 500 mg - all other therapeutic products

United States - English - NLM (National Library of Medicine)

advanced accelerator applications usa, inc - gozetotide (unii: 9ag41l3aoq) (gozetotide - unii:9ag41l3aoq) - locametz, after radiolabeling with gallium-68, is indicated for positron emission tomography (pet) of prostate-specific membrane antigen (psma)-positive lesions in men with prostate cancer: - with suspected metastasis who are candidates for initial definitive therapy. - with suspected recurrence based on elevated serum prostate-specific antigen (psa) level. - for selection of patients with metastatic prostate cancer, for whom lutetium lu 177 vipivotide tetraxetan psma-directed therapy is indicated. none. risk summary locametz is not indicated for use in females. there are no available data with gallium ga 68 gozetotide use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. all radiopharmaceuticals, including locametz, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of radiation dose. animal reproduction studies have not been conducted with gallium ga 68 gozetotide. risk summar

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - desferrioxamine mesilate - powder for solution for injection - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - desferrioxamine mesilate - powder for solution for injection - 2gram

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ire elit sa-nv - 68 ge - 68 ga ; 68 ge - 68 ga - radionuclide generator - 0,74-1,85 gbq - germanium (ge-68) chloride; gallium (ga-68) chloride - other diagnostic radiopharmaceuticals

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eckert & ziegler radiopharma gmbh - 68 ge - 68 ga - radionuclide generator - 0,74-1,85 gbq - germanium (ge-68) chloride; gallium (ga-68) chloride - various diagnostic radiopharmaceuticals

United States - English - NLM (National Library of Medicine)

telix pharmaceuticals (us) inc. - gozetotide (unii: 9ag41l3aoq) (gozetotide - unii:9ag41l3aoq) - illuccix, after radiolabeling with ga 68, is indicated for positron emission tomography (pet) of prostate-specific membrane antigen (psma) positive lesions in men with prostate cancer: - with suspected metastasis who are candidates for initial definitive therapy. - with suspected recurrence based on elevated serum prostate-specific antigen (psa) level. - for selection of patients with metastatic prostate cancer, for whom lutetium lu 177 vipivotide tetraxetan psma-directed therapy is indicated. none risk summary illuccix is not indicated for use in females. there are no available data with gallium ga 68 gozetotide injection use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. all radiopharmaceuticals, including illuccix, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose. animal reproduction studies have not been conducted with gallium ga 68 gozetotide. ri